Biblio

Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is T  [Clear All Filters]
2022
Vagnozzi RJ, McKinsey TA. T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR. Cell Stem Cell. 2022;29(3):352-354.
Zuo L, Kuo W-T, Cao F, Chanez-Paredes SD, Zeve D, Mannam P, Jean-François L, Day A, W Graham V, Sweat YY, et al. Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. Gut. 2022.
Cordeiro JM, Barão VAR, de Avila ED, Husch JFA, Yang F, van den Beucken JJJP. Tailoring Cu-loaded electrospun membranes with antibacterial ability for guided bone regeneration. Biomater Adv. 2022;139:212976.
Ancel J, Guecamburu M, V Da Silva M, Schilfarth P, Boyer L, Pilette C, Martin C, Devillier P, Berger P, Zysman M, et al. [Take-home messages from the COPD 2021 biennial of the French Society of Respiratory Diseases. Understanding to so as to better innovate]. Rev Mal Respir. 2022.
Pavlovich MJ. Taking the guesswork out of journal submission with Community Review. Cell Stem Cell. 2022;29(5):663-666.
Birnbaum F, Eguchi A, Pardon G, C Y Chang A, Blau HM. Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates. NPJ Regen Med. 2022;7(1):19.
Zhang Z, Zhou X, Guo J, Zhang F, Qian Y, Wang G, Duan M, Wang Y, Zhao H, Yang Z, et al. TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment. J Transl Med. 2022;20(1):320.
Katsanos D, Barkoulas M. Targeted DamID in reveals a direct role for LIN-22 and NHR-25 in antagonizing the epidermal stem cell fate. Sci Adv. 2022;8(5):eabk3141.
Pourradi NMohammad A, Babaei H, Hamishehkar H, Baradaran B, Shokouhi-Gogani B, Shanehbandi D, Ghorbani M, Azarmi Y. Targeted delivery of doxorubicin by Thermo/pH-responsive magnetic nanoparticles in a rat model of breast cancer. Toxicol Appl Pharmacol. 2022:116036.
Cruz AFilipa, Fonseca NA, Malheiro ARita, Melo JB, Gaspar MManuela, Fernandes R, Moura V, Simões S, Moreira JNuno. Targeted liposomal doxorubicin/ceramides combinations: the importance to assess the nature of drug interaction beyond bulk tumor cells. Eur J Pharm Biopharm. 2022.
Ali N, Sharma AArunkumar, de Rezende ACarolina P, Otegbeye F, Latif BMuhammad, Kerbauy MNassif, Cooper BW, Sanchez G, Metheny L, Bal SK, et al. Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022.
Huang T, Zhang T, Gao J. Targeted mitochondrial delivery: A therapeutic new era for disease treatment. J Control Release. 2022.
Zhang YJ, Xing Z, Liu T, Tang M, Mi L, Zhu J, Wu W, Wei T. Targeted therapy and drug resistance in thyroid cancer. Eur J Med Chem. 2022;238:114500.
Narayan N, Huntly BJP. Targeting AML at the intersection of epigenetics and signaling. Sci Signal. 2022;15(730):eabo0059.
Loh J, Ang YLi En, Jain A, Yeong J, Sundar R. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies. JCO Precis Oncol. 2022;6:e2200208.
Kumar M, Pandey SKumar, Lalhall A, Sharma R, Sharma RK, Wangoo N. Targeting bacterial biofilms using vancomycin and multivalent cell-penetrating peptide labeled quantum dots. J Biomed Mater Res B Appl Biomater. 2022.
Zattoni IFatima, Delabio LCarani, Dutra Jde Paula, Kita DHenrique, Scheiffer G, Hembecker M, Pereira Gda Silva, Moure VRotuno, Valdameri G. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 2022;237:114346.
Paul S, Sinha S, Kundu CNath. Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors. Pharmacol Res. 2022:106425.
Funasaki S, Mehanna S, Ma W, Nishizawa H, Kamikubo Y, Sugiyama H, Ikeda S, Motoshima T, Hasumi H, W Linehan M, et al. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate. Cancer Sci. 2022.
Lazer LMary, Kesavan Y, Gor R, Ramachandran I, Pathak S, Narayan S, Anbalagan M, Ramalingam S. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles. Colloids Surf B Biointerfaces. 2022;217:112612.
Zhu G-Q, Wang Y, Wang B, Liu W-R, Dong S-S, Chen E-B, Cai J-L, Wan J-L, Du J-X, Song L-N, et al. Targeting HNRNPM inhibits cancer stemness and enhances antitumor immunity in Wnt-activated hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022.
Liu J, Peng Y, Inuzuka H, Wei W. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy. Semin Cancer Biol. 2022.
Li J, Sha Z, Zhu X, Xu W, Yuan W, Yang T, Jin B, Yan Y, Chen R, Wang S, et al. Targeting miR-30d reverses pathological cardiac hypertrophy. EBioMedicine. 2022;81:104108.
Koelman EMR, Yeste-Vázquez A, Grossmann TN. Targeting the interaction of β-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling. Bioorg Med Chem. 2022;70:116920.
Mir C, Garcia-Mayea Y, LLeonart ME. Targeting the "undruggable": RNA-binding proteins in the spotlight in cancer therapy. Semin Cancer Biol. 2022.

Pages